Inferred from the database from the CAMOIP website, the TENM2 mutant population generally enjoys a higher level of immunotherapy-contributed factors, PD-1 (PDCD1), neoantigens, and tumor mutation burden, for example (Figures 8(a)–8(c)). Here, PDCD1 is linked to neoplasm.